Ge Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ge Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Cheng-Ke Xie
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
1 shared publication - Cheng-Yu Liao
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
1 shared publication - Dan-Feng Wang
Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China
1 shared publication - Hao-Xiang Zhang
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
1 shared publication - Hong-Yi Lin
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
1 shared publication Hou-Juan Zhu
Institute of Materials Research and Engineering A*STAR (Agency for Science, Technology and Research, Innovis, Singapore
1 shared publication
Latest Publications
- Open Access
- 22 November 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Targeting SERPINB3–MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy
Cuproptosis, a newly identified form of cell death, is closely linked to copper homeostasis and protein lipoylation. Using a multi-omics approach, we firstly reveal that SERPINB3 confers cuproptosis resistance in pancreatic cancer and functions as a theranostic biomarker. Mechanistically, SERPINB3 inhibits FDX1 transcription by activating the MAPK signaling pathway, thereby conferring cuproptosis resistance. We further demonstrated that SERPINB3 directly interacts with MEK1, impeding its chaperone-mediated autophagic degradation, which ultimately leads to sustained activation of the MAPK signaling pathway. Additionally, we found that SERPINB3 promotes pancreatic cancer immune evasion by upregulating PD-L1 expression on tumor cells. This phenomenon motivated the development of a triple-combination strategy consisting of MAPK inhibition, cuproptosis induction, and αPD-1 therapy for pancreatic cancer patients with high SERPINB3 expression. To this end, we further developed a metal-organic framework (MOF) loaded with both copper ions and MEK inhibitor, which significantly triggers tumor-specific cuproptosis and enhances antitumor immunity. In summary, SERPINB3 serves as a predictive biomarker to inform therapeutic strategies targeting cuproptosis, thereby establishing a novel paradigm for cancer immunotherapy that integrates metal biology, targeted therapy, and immune modulation.
- 22 November 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Open AccessTargeting SERPINB3–MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy
Cuproptosis, a newly identified form of cell death, is closely linked to copper homeostasis and protein lipoylation. Using a multi-omics approach, we firstly reveal that SERPINB3 confers cuproptosis resistance in pancreatic cancer and functions as a theranostic biomarker. Mechanistically, SERPINB3 inhibits FDX1 transcription by activating the MAPK signaling pathway, thereby conferring cuproptosis resistance. We further demonstrated that SERPINB3 directly interacts with MEK1, impeding its chaperone-mediated autophagic degradation, which ultimately leads to sustained activation of the MAPK signaling pathway. Additionally, we found that SERPINB3 promotes pancreatic cancer immune evasion by upregulating PD-L1 expression on tumor cells. This phenomenon motivated the development of a triple-combination strategy consisting of MAPK inhibition, cuproptosis induction, and αPD-1 therapy for pancreatic cancer patients with high SERPINB3 expression. To this end, we further developed a metal-organic framework (MOF) loaded with both copper ions and MEK inhibitor, which significantly triggers tumor-specific cuproptosis and enhances antitumor immunity. In summary, SERPINB3 serves as a predictive biomarker to inform therapeutic strategies targeting cuproptosis, thereby establishing a novel paradigm for cancer immunotherapy that integrates metal biology, targeted therapy, and immune modulation.